Immuneering Corp

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Immuneering Corp advances oncology focus with promising preclinical data

Immuneering Corp (IMRX) is making significant strides in oncology with promising preclinical data and a strategic focus on developing cancer treatments with better tolerability.
While facing challenges in addressing resistance and clarifying MEK inhibitor activity, the company's unique approach and strong response profiles position them well for future growth.
Opportunities lie in advancing pipeline assets, optimizing clinical trial outcomes through informatics, and leveraging expertise in relevant cancer types for Phase 2a success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board.

Immuneering Launches Pancreatic Cancer Advisory Board

Amicus Therapeutics

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors.

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy.

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer - - Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End - - Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates.

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - - Preclinical Data Presented at AACR Demonstrates that Combining IMM-1-104 with Chemotherapies Used in the Treatment of First-line Pancreatic Cancer Yields Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - Initial PK, PD and Safety Data from Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations expected in 2H 2024 - CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided business updates.

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Various names in the biotech sector are seeing big moves in today's session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ: IMRX ) is certainly one such company generating outsized interest today.

Why is Immuneering (IMRX) Stock Up 24% Today?

- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA submission for PDAC - - Phase 2a trial of IMM-1-104 includes multiple arms open to first-line pancreatic cancer patients, as well as arms open to patients with second-line pancreatic cancer, RAS-mutant melanoma, and RAS-mutant lung cancer - - Company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024 - CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

BioAtla, Inc

Rockwell Medical

With the third quarter in full swing, the bulls have not lost their grip on equities.

3 Penny Stocks With 735% Average Upside, According to Wall Street

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company's pipeline, platform, and business strategy.

Immuneering to Present at the Jefferies Global Healthcare Conference

- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided business updates.

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recognizes the importance of early detection and treatment during Melanoma Awareness Month, and highlights RAS mutant melanoma as the focus of one of the five arms in its ongoing Phase 2a clinical study for its lead program IMM-1-104.

Immuneering Recognizes Melanoma Awareness Month

- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone - - Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024, to discuss the company's pipeline, platform, and business strategy.

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion of the Phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IMM-6-415 and establish a candidate recommended Phase 2 dose (RP2D) - -Initial PK, PD and safety data expected in 2024 - CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations.

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg - - Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity - - Phase 2a portion of the study underway with three monotherapy and two combination arms in earlier lines of treatment, with initial data from multiple arms expected in 2024 - - Immuneering will host an investor call today at 8:30 a.m. ET. - CAMBRIDGE, Mass.

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J.

Immuneering Appoints Thomas J. Schall, Ph.D.

- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) -

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Bioline RX

Candel Therapeutics

Oncolytics Biotech, Inc.

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology. Read the full article on Investoorideas.com Research Nester says, "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.

News for Immuneering Corp Stock (IMRX)